prikaz prve stranice dokumenta Sugamadeks, novi antagonist mišićnih relaksatora
  Download
PDF 288.98 KB
Professional paper - Professional paper
Sugamadeks, novi antagonist mišićnih relaksatora
Liječnički vjesnik, 133 (2011), 3-4; 106-110. urn:nbn:hr:239:186706
Kvolik, Slavica; Ikić, Višnja; Jukić, Marko

Cite this document

Kvolik, S., Ikić, V. & Jukić, M. (2011). Sugamadeks, novi antagonist mišićnih relaksatora. Liječnički vjesnik, 133. (3-4), 106-110. Retrieved from https://urn.nsk.hr/urn:nbn:hr:239:186706

Kvolik, Slavica, et al. "Sugamadeks, novi antagonist mišićnih relaksatora." Liječnički vjesnik, vol. 133, no. 3-4, 2011, pp. 106-110. https://urn.nsk.hr/urn:nbn:hr:239:186706

Kvolik, Slavica, Višnja Ikić and Marko Jukić. "Sugamadeks, novi antagonist mišićnih relaksatora." Liječnički vjesnik 133, no. 3-4 (2011): 106-110. https://urn.nsk.hr/urn:nbn:hr:239:186706

Kvolik, S., Ikić, V. and Jukić, M. (2011) 'Sugamadeks, novi antagonist mišićnih relaksatora', Liječnički vjesnik, 133(3-4), pp. 106-110. Available at: https://urn.nsk.hr/urn:nbn:hr:239:186706 (Accessed 16 November 2024)

Kvolik S, Ikić V, Jukić M. Sugamadeks, novi antagonist mišićnih relaksatora. Liječnički vjesnik [Internet]. 2011 [cited 2024 November 16];133(3-4):106-110. Available at: https://urn.nsk.hr/urn:nbn:hr:239:186706

S. Kvolik, V. Ikić and M. Jukić, "Sugamadeks, novi antagonist mišićnih relaksatora", Liječnički vjesnik, vol. 133, no. 3-4, pp. 106-110, 2011. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:239:186706. [Accessed: 16 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (croatian)Sugamadeks, novi antagonist mišićnih relaksatora
Title (english)Sugammadex, a new drug for Reversion of Muscle Relaxants
AuthorSlavica Kvolik
MBZ: 259895
AuthorVišnja Ikić
AuthorMarko Jukić
Author's institution(Clinical hospital center Osijek)
Author's institutionUniversity of Split
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Abstract (croatian)
Sugamadeks je novi lijek za reverziju neuromuskularnog bloka. Po kemijskoj građi on je alfa-ciklodekstrin s lipofilnom unutrašnjom stranom molekule koja omogućuje stvaranje stabilnih kompleksa, tzv. enkapsulaciju molekula mišićnih relaksatora, napose rokuronija. Fizička enkapsulacija novi je mehanizam eliminacije relaksatora s mjesta njegova učinka. Ona omogućuje brzu i potpunu reverziju dubokog i plitkog neuromuskularnog bloka ovisnu o primijenjenoj dozi. Sugamadeks nema neželjenih kolinergičkih muskarinskih nuspojava koje se opažaju nakon primjene inhibitora kolinesteraze neostigmina i edrofonija kao što su bradikardija, hipersalivacija i abdominalne boli. Nakon primjene prilagođene doze sugamadeksa učinak rokuronija može biti kratak kao i učinak sukcinilkolina. Ovo je osobito važno u situacijama kada se bolesnik ne može intubirati niti ventilirati ili kada je kirurški zahvat nepredviđeno brzo završen. Kliničke studije na većem broju bolesnika pokazat će omjer koristi i rizika njegove primjene u skupinama osjetljivih bolesnika, osobito može li sugamadeks smanjiti učestalost poslijeoperacijskih respiracijskih komplikacija.
Abstract (english)
Sugammadex is a new pharmacological agent for neuromuscular block reversion. It is a cyclic oligosaccharide, a gamma cyclodextrin with lipophylic inner coat that enables forming of stable complexes with steroidal neuromuscular blocking drugs, especially with rocuronium. A physical encapsulation of the relaxants is a novel elimination pathway and it produces fast and complete reversion of both deep and shallow neuromuscular block. Consequently, sugammadex has no unwanted cholinergic muscarinic effects observed with cholinesterase inhibitors such as bradycardia, hypersalivation, and increased gastrointestinal motility. Since the effects of sugammadex are dose dependent it can very rapidly reverse the effects of rocuronium. After the adjusted dose of sugammadex was given, the duration of action of rocuronium can be made as short as that of succinylcholine. This characteristic is especially important in the ’can’t intubate, can’t ventilate’ situation and after surgical procedure was unexpectedly finished. Clinical studies involving more patients are needed to show the real risk-benefit profile and safety in the special patients’ populations
Keywords (croatian)
Keywords (english)
Languagecroatian
Publication typeProfessional paper - Professional paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleLiječnički vjesnik
Numberingvol. 133, no. 3-4, pp. 106-110
p-ISSN0024-3477
e-ISSN1849-2177
URN:NBNurn:nbn:hr:239:186706
Publication2011
Document URLhttps://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=253298
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2020-02-05 13:44:44